Comparative Pharmacology
Head-to-head clinical analysis: GVS versus HUMATIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GVS versus HUMATIN.
GVS vs HUMATIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GVS is not a recognized drug. No mechanism of action available.
Aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and production of nonfunctional proteins.
1 mg IV bolus every 3 minutes up to 3 doses as needed for status epilepticus; max total dose 3 mg.
15-25 mg/kg/day orally in 4 divided doses for hepatic coma; 50 mg/kg/day orally in 4 divided doses for infectious diarrhea, max 4 g/day.
None Documented
None Documented
Terminal half-life: 3-5 hours in healthy adults; prolonged to 8-12 hours in severe renal impairment (CrCl <30 mL/min).
2-3 hours (serum half-life of absorbed fraction); clinically negligible due to minimal systemic absorption
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other.
Primarily unchanged in feces (~90%); small amount absorbed is excreted renally as unchanged drug (~1%)
Category C
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic